yorkshire cancer research

yorkshire cancer research Company Information

Share YORKSHIRE CANCER RESEARCH
Live 
MatureLargeHigh

Company Number

01919823

Industry

Other human health activities

 

Directors

Sandra Dodson

Yvette Oade

View All

Shareholders

-

Group Structure

View All

Contact

Registered Address

unit a3 hornbeam square west, harrogate, north yorkshire, HG2 8PA

yorkshire cancer research Estimated Valuation

£31.8m

Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £31.8m based on a Turnover of £31.7m and 1x industry multiple (adjusted for size and gross margin).

yorkshire cancer research Estimated Valuation

£129.4m

Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £129.4m based on an EBITDA of £16.9m and a 7.67x industry multiple (adjusted for size and gross margin).

yorkshire cancer research Estimated Valuation

£280m

Pomanda estimates the enterprise value of YORKSHIRE CANCER RESEARCH at £280m based on Net Assets of £113.9m and 2.46x industry multiple (adjusted for liquidity).

Edit your figures and get a professional valuation report.

Yorkshire Cancer Research Overview

Yorkshire Cancer Research is a live company located in north yorkshire, HG2 8PA with a Companies House number of 01919823. It operates in the other human health activities sector, SIC Code 86900. Founded in June 1985, it's largest shareholder is unknown. Yorkshire Cancer Research is a mature, large sized company, Pomanda has estimated its turnover at £31.7m with high growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Yorkshire Cancer Research Health Check

Pomanda's financial health check has awarded Yorkshire Cancer Research a 5 rating. We use a traffic light system to show it exceeds the industry average on 8 measures and has 3 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating5out of 5
positive_score

8 Strong

positive_score

1 Regular

positive_score

3 Weak

size

Size

annual sales of £31.7m, make it larger than the average company (£708.9k)

£31.7m - Yorkshire Cancer Research

£708.9k - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 16%, show it is growing at a faster rate (7.2%)

16% - Yorkshire Cancer Research

7.2% - Industry AVG

production

Production

with a gross margin of 38.5%, this company has a comparable cost of product (38.5%)

38.5% - Yorkshire Cancer Research

38.5% - Industry AVG

profitability

Profitability

an operating margin of 52.2% make it more profitable than the average company (5.1%)

52.2% - Yorkshire Cancer Research

5.1% - Industry AVG

employees

Employees

with 102 employees, this is above the industry average (18)

102 - Yorkshire Cancer Research

18 - Industry AVG

paystructure

Pay Structure

on an average salary of £40.1k, the company has a higher pay structure (£26.5k)

£40.1k - Yorkshire Cancer Research

£26.5k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £311.1k, this is more efficient (£45.6k)

£311.1k - Yorkshire Cancer Research

£45.6k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 39 days, this is later than average (20 days)

39 days - Yorkshire Cancer Research

20 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 4 days, this is quicker than average (18 days)

4 days - Yorkshire Cancer Research

18 days - Industry AVG

stockdays

Stock Days

it holds stock equivalent to 0 days, this is less than average (13 days)

0 days - Yorkshire Cancer Research

13 days - Industry AVG

cashbalance

Cash Balance

has cash to cover current liabilities for 176 weeks, this is more cash available to meet short term requirements (128 weeks)

176 weeks - Yorkshire Cancer Research

128 weeks - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 3.8%, this is a lower level of debt than the average (22%)

3.8% - Yorkshire Cancer Research

22% - Industry AVG

YORKSHIRE CANCER RESEARCH financials

EXPORTms excel logo

Yorkshire Cancer Research's latest turnover from March 2024 is £31.7 million and the company has net assets of £113.9 million. According to their latest financial statements, Yorkshire Cancer Research has 102 employees and maintains cash reserves of £15.3 million as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Turnover31,736,15232,812,40625,831,52120,288,90618,716,73712,789,32511,031,79620,891,4236,818,40517,778,1075,139,5204,199,9786,212,1244,220,4385,182,261
Other Income Or Grants000000000000000
Cost Of Sales19,509,54020,607,12616,470,34813,373,06711,976,0648,333,5346,984,31112,793,4064,258,48811,077,1923,186,2112,534,7633,576,8312,373,1742,940,606
Gross Profit12,226,61212,205,2809,361,1736,915,8396,740,6734,455,7914,047,4858,098,0172,559,9176,700,9151,953,3091,665,2152,635,2931,847,2642,241,655
Admin Expenses-4,347,729-7,671,826-8,995,657-8,453,341-190,416-912,989-1,806,876-11,585,836980,420-10,396,1291,888,2053,711,9724,752,3723,995,8335,322,693
Operating Profit16,574,34119,877,10618,356,83015,369,1806,931,0895,368,7805,854,36119,683,8531,579,49717,097,04465,104-2,046,757-2,117,079-2,148,569-3,081,038
Interest Payable000000000000000
Interest Receivable000000000000000
Pre-Tax Profit13,115,03216,778,60115,014,86712,469,4195,629,2114,437,2184,779,99815,754,4241,281,02813,522,70559,657-2,038,228-2,114,191-2,146,253-3,079,834
Tax000000000000000
Profit After Tax13,115,03216,778,60115,014,86712,469,4195,629,2114,437,2184,779,99815,754,4241,281,02813,522,70559,657-2,038,228-2,114,191-2,146,253-3,079,834
Dividends Paid000000000000000
Retained Profit13,115,03216,778,60115,014,86712,469,4195,629,2114,437,2184,779,99815,754,4241,281,02813,522,70559,657-2,038,228-2,114,191-2,146,253-3,079,834
Employee Costs4,092,0862,994,0542,468,8112,143,8361,725,4451,425,5811,258,7651,147,3611,084,014886,953853,300755,331670,599732,429762,508
Number Of Employees1027361524137343230282119192223
EBITDA*16,877,89319,983,41918,445,15115,424,0746,960,7565,396,4635,874,68919,721,4751,626,84117,145,19696,310-2,017,852-2,117,079-2,118,637-3,051,948

* Earnings Before Interest, Tax, Depreciation and Amortisation

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Tangible Assets2,828,413985,538226,519176,900150,89187,71592,52393,562125,033240,761155,735148,765168,272169,554155,616
Intangible Assets34,46535,6180000000000000
Investments & Other88,215,72773,516,15258,565,91340,958,05728,157,48833,861,40930,487,06733,859,05122,169,32017,238,9629,008,1489,406,06112,339,01413,277,35213,668,002
Debtors (Due After 1 year)000000000000000
Total Fixed Assets91,078,60574,537,30858,792,43241,134,95728,308,37933,949,12430,579,59033,952,61322,294,35317,479,7239,163,8839,554,82612,507,28613,446,90613,823,618
Stock & work in progress42,61931,64934,55006,0110014,04522,0780005,1555,1004,147
Trade Debtors3,435,607584,889626,353425,2612,883,0733,028,6781,476,7964,215,646382,0711,627,340182,172569,608802,110823,8892,674,329
Group Debtors000000000000000
Misc Debtors8,634,2339,638,5118,174,4615,981,0986,808,5572,008,6041,682,759708,005730,725338,525123,915157,001179,721116,513159,725
Cash15,260,43319,496,43819,901,96528,109,45222,218,62614,889,70614,248,2694,500,3112,841,0735,874,0372,247,7052,701,227710,447444,567481,649
misc current assets000000000000000
total current assets27,372,89229,751,48728,737,32934,515,81131,916,26719,926,98817,407,8249,438,0073,975,9477,839,9022,553,7923,427,8361,697,4331,390,0693,319,850
total assets118,451,497104,288,79587,529,76175,650,76860,224,64653,876,11247,987,41443,390,62026,270,30025,319,62511,717,67512,982,66214,204,71914,836,97517,143,468
Bank overdraft000000000000000
Bank loan000000000000000
Trade Creditors 246,546529,559314,27269,89200000000000
Group/Directors Accounts20220220220220220220220220220220220220200
other short term finances000000000000000
hp & lease commitments000000000000000
other current liabilities4,259,9092,929,2263,164,0806,544,3343,657,5262,883,2751,461,2251,230,7451,186,4161,037,3691,255,9762,676,6102,604,993931,9241,591,685
total current liabilities4,506,6573,458,9873,478,5546,614,4283,657,7282,883,4771,461,4271,230,9471,186,6181,037,5711,256,1782,676,8122,605,195931,9241,591,685
loans000000000000000
hp & lease commitments000000000000000
Accruals and Deferred Income000000000000000
other liabilities000000000000000
provisions0000054,92828,32800000000
total long term liabilities0000054,92828,32800000000
total liabilities4,506,6573,458,9873,478,5546,614,4283,657,7282,938,4051,489,7551,230,9471,186,6181,037,5711,256,1782,676,8122,605,195931,9241,591,685
net assets113,944,840100,829,80884,051,20769,036,34056,566,91850,937,70746,497,65942,159,67325,083,68224,282,05410,461,49710,305,85011,599,52413,905,05115,551,783
total shareholders funds113,944,840100,829,80884,051,20769,036,34056,566,91850,937,70746,497,65942,159,67325,083,68224,282,05410,461,49710,305,85011,599,52413,905,05115,551,783
Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Operating Activities
Operating Profit16,574,34119,877,10618,356,83015,369,1806,931,0895,368,7805,854,36119,683,8531,579,49717,097,04465,104-2,046,757-2,117,079-2,148,569-3,081,038
Depreciation271,98677,00188,32154,89429,66727,68320,32837,62247,34448,15231,20628,905029,93229,090
Amortisation31,56629,3120000000000000
Tax000000000000000
Stock10,970-2,90134,550-6,0116,0110-14,045-8,03322,07800-5,155559534,147
Debtors1,846,4401,422,5862,394,455-3,285,2714,654,3481,877,727-1,764,0963,810,855-853,0691,659,778-420,522-255,22241,429-1,893,6522,834,054
Creditors-283,013215,287244,38069,89200000000000
Accruals and Deferred Income1,330,683-234,854-3,380,2542,886,808774,2511,422,050230,48044,329149,047-218,607-1,420,63471,6171,673,069-659,7611,591,685
Deferred Taxes & Provisions0000-54,92826,60028,32800000000
Cash flow from operations16,068,15318,544,16712,880,27221,672,0563,019,7204,967,3867,911,63815,962,9822,606,87915,266,811-903,802-1,685,858-485,494-885,699-4,298,464
Investing Activities
capital expenditure00000-3,259,6763,350,790-11,695,882-4,572,365-8,066,139456,7693,668,109716,026860,1621,287,501
Change in Investments14,699,57514,950,23917,607,85612,800,569-5,703,9213,374,342-3,371,98411,689,7314,930,3588,230,814-397,913-2,932,953-938,338-390,65013,668,002
cash flow from investments-14,699,575-14,950,239-17,607,856-12,800,5695,703,921-6,634,0186,722,774-23,385,613-9,502,723-16,296,953854,6826,601,0621,654,3641,250,812-12,380,501
Financing Activities
Bank loans000000000000000
Group/Directors Accounts00000000000020200
Other Short Term Loans 000000000000000
Long term loans000000000000000
Hire Purchase and Lease Commitments000000000000000
other long term liabilities000000000000000
share issue000302,830-442,0121,321,567-479,400297,85295,990744,554-191,336499,52118,631,617
interest000000000000000
cash flow from financing000302,830-442,0121,321,567-479,400297,85295,990744,554-191,134499,52118,631,617
cash and cash equivalents
cash-4,236,005-405,527-8,207,4875,890,8267,328,920641,4379,747,9581,659,238-3,032,9643,626,332-453,5221,990,780265,880-37,082481,649
overdraft000000000000000
change in cash-4,236,005-405,527-8,207,4875,890,8267,328,920641,4379,747,9581,659,238-3,032,9643,626,332-453,5221,990,780265,880-37,082481,649

yorkshire cancer research Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for yorkshire cancer research. Get real-time insights into yorkshire cancer research's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Yorkshire Cancer Research Competitor Analysis

competitor_analysis_table_img

Perform a competitor analysis for yorkshire cancer research by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other large companies, companies in HG2 area or any other competitors across 12 key performance metrics.

yorkshire cancer research Ownership

YORKSHIRE CANCER RESEARCH group structure

Yorkshire Cancer Research has 2 subsidiary companies.

Ultimate parent company

YORKSHIRE CANCER RESEARCH

01919823

2 subsidiaries

YORKSHIRE CANCER RESEARCH Shareholders

--

yorkshire cancer research directors

Yorkshire Cancer Research currently has 16 directors. The longest serving directors include Mrs Sandra Dodson (Apr 2014) and Dr Yvette Oade (Apr 2014).

officercountryagestartendrole
Mrs Sandra DodsonEngland71 years Apr 2014- Director
Dr Yvette OadeEngland65 years Apr 2014- Director
Mr Robert NdawulaUnited Kingdom50 years Oct 2018- Director
Ms Elizabeth RichardsUnited Kingdom67 years Nov 2018- Director
Mrs Clare FieldEngland57 years Mar 2019- Director
Dr James RiceEngland56 years Jul 2020- Director
Mr Craig BonnarEngland51 years Jan 2021- Director
Mr Samuel JennerEngland40 years Jun 2022- Director
Mr Matthew JohnsonEngland57 years Jun 2022- Director
Sir Robert LanglandsEngland72 years Sep 2022- Director

P&L

March 2024

turnover

31.7m

-3%

operating profit

16.6m

0%

gross margin

38.6%

+3.57%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2024

net assets

113.9m

+0.13%

total assets

118.5m

+0.14%

cash

15.3m

-0.22%

net assets

Total assets minus all liabilities

yorkshire cancer research company details

company number

01919823

Type

Private Ltd By Guarantee w/o Share Cap

industry

86900 - Other human health activities

incorporation date

June 1985

age

39

incorporated

UK

ultimate parent company

None

accounts

Full Accounts

last accounts submitted

March 2024

previous names

yorkshire cancer research campaign (December 1997)

accountant

-

auditor

RSM UK AUDIT LLP

address

unit a3 hornbeam square west, harrogate, north yorkshire, HG2 8PA

Bank

LLOYDS TSB BANK PLC

Legal Advisor

-

yorkshire cancer research Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to yorkshire cancer research.

yorkshire cancer research Capital Raised & Share Issues BETA

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for YORKSHIRE CANCER RESEARCH. This can take several minutes, an email will notify you when this has completed.

yorkshire cancer research Companies House Filings - See Documents

datedescriptionview/download